Article
Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
Biochemical pharmacology - 1 Apr 2018
Yan Xiaohui, Li Pengfei, Zhan Yihong, Qi Miao, Liu Jin, An Zhifeng, Yang Weiwei, Xiao Hui, Wu Hongmei, Qi Yitao, Shao Huanjie
Abstract excerpt
Non-small cell lung cancer (NSCLC) is the most common malignancy worldwide. A significant fraction of NSCLC carries activating mutations in epidermal growth factor receptor (EGFR) or RAS oncogene. Dihydroartemisinin (DHA) is a semisynthetic derivative of the herbal antimalarial drug artemisinin that has been recently reported to exhibit anti-cancer activity. To develop new therapeutic strategies for NSCLC, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.